Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 313
- Registration Number
- NCT00545844
First Step With Singulair® Therapy (0476-323)
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 399
- Registration Number
- NCT00545324
Health Assessment Study (0954-946)
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 143
- Registration Number
- NCT00541684
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 516
- Registration Number
- NCT00542087
Eze/Simva Switch Study in Diabetics (0653A-807)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 648
- Registration Number
- NCT00541697
A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)
Phase 3
Withdrawn
- Conditions
- Asthma, Bronchial
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT00540839
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
Phase 4
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 314
- Registration Number
- NCT00536380
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1289
- Registration Number
- NCT00535405
The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
Phase 4
Completed
- Conditions
- Exercise-induced Bronchoconstriction (EIB)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 364
- Registration Number
- NCT00534976
A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 672
- Registration Number
- NCT00521599